View Clinical Trial (Medical Research Study)
Blood Flow MRI for Monitoring of Glioma Angiogenesis
| City: |
|
Boston |
| State: |
|
Massachusetts |
| Zip Code: |
|
02215 |
| Conditions: |
|
Brain Tumors |
| Purpose: |
|
The investigators are studying the use of an advanced magnetic resonance imaging (MRI)
technique for measuring blood flow into brain tumors. This technique does not use
radioactive tracers, and it can provide high quality images that can be obtained in a
standard MRI scanner.
|
| Study Summary: |
|
Our goals are:
1. To compare the blood flow measured with this technique with measures of tumor blood
vessel density in pieces of the tumor surgically removed as a normal part of clinical
treatment. This will confirm a relationship between the imaging measurements and the
microscopic characteristics of tumors.
2. To compare the blood flow in tumors before therapy with the concentration of choline,
an indicator of cell proliferation. This choline concentration can be measured with
another MRI technique. This information will demonstrate the relationship between cell
proliferation and blood supply and will also determine whether the choline measurement
adds additional information that is clinically necessary.
3. To determine the reproducibility of blood flow measurements in tumors. This is
necessary to better understand the sensitivity of the technique to changes in flow
caused by a treatment or changes in tumor vascularity.
4. To monitor changes in blood flow after initial treatment. Since sometimes tumors can
reappear, the repeated measures will help determine how useful this new imaging
technique is at detecting such recurring tumors.
|
| Criteria: |
|
Inclusion Criteria:
- diagnosed with or are suspected of having a glioma
Exclusion Criteria:
- contraindications to MRI which may include the following
1. Pacemaker
2. MRI incompatible metal implant
3. Recently implanted vascular clip
4. History of claustrophobia
5. Metal fragment within the eye
Subjects who have received nonstandard therapy may be excluded if the therapy might alter
tumor blood flow or other imaging characteristic.
|
| NCT ID: |
|
NCT01538264 |
| Primary Contact: |
|
Principal Investigator
David C Alsop, PhD
Beth Israel Deaconess Medical Center
Kelly Roth, BA
Phone: 617-667-0290 ext. 7-0290
Email: karoth@bidmc.harvard.edu
|
| Backup Contact: |
|
Email: mfox2@bidmc.harvard.edu
Meaghan Fox, BS
Phone: 617-667-5915 ext. 7-5915
|
| Location Contact: |
|
Boston, Massachusetts 02215
United States
Kelly Roth, BA
Phone: 617-667-0290
Email: karoth@bidmc.harvard.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 19, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|